申请人:VIVACELL BIOTECHNOLOGY ESPANA S.L.
公开号:US10766855B2
公开(公告)日:2020-09-08
Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein R═—C(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1α and HIF-2α proteins, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, show neuroprotective activity in vitro and in vivo, antidiabetic activity and reduce the levels of lipids in vivo, and increase the plasma levels of Erythropoietin in vivo. The triterpenoid derivatives described act also in a selective manner and do not induce Nrf2 activation, NF-κB inhibition, STAT3 inhibition, and TGR5 activation, which are known activities of the natural triterpenoid precursors. Said triterpenoid derivatives are useful in the treatment of conditions and diseases which are responsive to HIF activation such as stroke, cerebral palsy, traumatic injuries and neurodegenerative diseases; and also IBD, myocardial ischaemia-reperfusion injury, acute lung injury, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.
描述了式 (I) 的三萜类衍生物和包含所述三萜类衍生物的组合物,其中 R═-C(O)NHOH.所述三萜类化合物和组合物具有结合 PHD2 的能力,可稳定 HIF-1α 和 HIF-2α 蛋白,激活不同类型细胞中的 HIF 通路,诱导人内皮血管细胞的血管生成,在体外和体内显示神经保护活性,具有抗糖尿病活性,降低体内血脂水平,提高体内红细胞生成素的血浆水平。所述三萜类衍生物还具有选择性作用,不会诱导 Nrf2 激活、NF-κB 抑制、STAT3 抑制和 TGR5 激活,这些都是天然三萜类前体的已知活性。所述三萜类衍生物可用于治疗对 HIF 活化有反应的病症和疾病,如中风、脑瘫、创伤性损伤和神经退行性疾病;以及肠道疾病、心肌缺血再灌注损伤、急性肺损伤、糖尿病和慢性伤口、器官移植、急性肾损伤或动脉疾病。